Non-small Cell Lung Cancer With EGFR-Activating Mutations
1 clinical trials · Condition
◉ Watch Non-small Cell Lung Cancer With EGFR-Activating Mutations
| Record | Firm | Date |
|---|---|---|
| ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC. (NCT01774721) | Pfizer | 2013-05-09 |
Track Non-small Cell Lung Cancer With EGFR-Activating Mutations automatically
Every clearance here is in the API, with alerts when new ones post.